Godavari Drugs Ltd (530317)

Healthcare · Pharmaceuticals · NSE · Updated 2 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹97.08 ↑ 13.49% (1Y)

🎯 Key Takeaways

Godavari Drugs Ltd is transitioning from a pure-play pharmaceutical manufacturer to a diversified life sciences entity by expanding into nutraceuticals and dietary supplements, pending shareholder approval at its 38th AGM on 25 September 2026. The company has maintained stable profitability with consistent operating margins and modest growth, but faces leverage constraints and a strategic pivot requiring capital reallocation.
Revenue declined 15.7% QoQ to ₹28 in Q1FY27.
⚠️ 1) The success of the nutraceutical expansion depends on shareholder approval at the 38th AGM and regulatory filings, which carry uncertainty given th

Market Cap

₹98

P/E Ratio

18.9

P/B Ratio

2.27

ROE

9.6%

ROCE

8.4%

Debt/Equity

1.42

Promoter

40.2%

✨ Ask AI About 530317 📊 Interactive Charts

📖 The Story

Godavari Drugs Ltd is transitioning from a pure-play pharmaceutical manufacturer to a diversified life sciences entity by expanding into nutraceuticals and dietary supplements, pending shareholder approval at its 38th AGM on 25 September 2026. The company has maintained stable profitability with consistent operating margins and modest growth, but faces leverage constraints and a strategic pivot requiring capital reallocation. This shift marks a pivotal phase in its lifecycle, moving beyond traditional generics into higher-margin adjacent segments.

📰 What's Happening

In its August 31, 2026 board meeting, Godavari Drugs approved amending its memorandum to include nutraceuticals and dietary supplements as a new business line, requiring special resolution approval at the 38th AGM scheduled for 25 September 2026. Management emphasized that the amendment will take effect upon shareholder approval and filing of Form MGT-14 with the Registrar of Companies. This strategic expansion signals intent to leverage existing manufacturing infrastructure and regulatory expertise to enter the fast-growing nutraceutical market, which management views as a natural extension of its pharmaceutical operations.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	24	27	22	33	28
Operating Profit	2	1	2	2	2
OPM %	9.7%	5.2%	8.4%	7.0%	6.9%
Net Profit	1	1	1	1	1
EPS	₹1.38	₹1.33	₹1.01	₹1.71	₹1.10

The company has demonstrated stable top-line performance with quarterly revenues hovering around ₹25-33 crore over the past year, though growth has been uneven. Operating margins have remained steady between 5.2% and 9.7%, supported by consistent operating profits of approximately ₹1-2 crore per quarter. Net profits and EPS have shown modest variation without a clear upward trend, suggesting the business is in a mature phase with limited organic growth, likely constrained by market saturation in generic pharmaceuticals and the early stages of diversification.

🔮 Management Outlook & What's Next

Management has not provided formal forward guidance on revenue or margin expectations for the nutraceutical segment, but has explicitly linked the proposed business line amendment to long-term growth ambitions beyond traditional pharmaceuticals. The revised memorandum and shareholder resolution are framed as strategic enablers for diversification, with management indicating the change will take effect upon AGM approval and ROC filing. No quantitative targets or timelines for contribution from the new segment have been disclosed in the filings to date.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	8	8	8	10
Reserves	34	36	38	60
Borrowings	59	62	74	76
Total Liabilities	127	143	162	200
Fixed Assets	34	33	31	30
Investments	0	0	0	0
Total Assets	127	143	162	200

The balance sheet shows a significant increase in total assets from ₹143 crore in March 2025 to ₹200 crore in March 2026, driven by rising borrowings from ₹62 crore to ₹76 crore and growth in equity and reserves. While equity has increased modestly from ₹8 crore to ₹10 crore, the sharp rise in debt suggests aggressive capital deployment, likely to fund expansion into nutraceuticals. The leverage ratio of 1.42 indicates high financial risk, especially as the company transitions into a new business area with uncertain returns.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	+11
Investing	-20
Financing	+8
Net Cash Flow	-0

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	52.6%	52.6%	40.2%	40.2%
FII	0.0%	0.0%	0.0%	0.0%
DII	0.5%	0.5%	2.5%	2.7%
Public	37.0%	36.9%	40.6%	42.8%
# Shareholders	7,720	7,483	7,300	6,722

Promoter holding has declined sharply from 52.61% in Q2FY26 to 40.23% by Q1FY27, while public shareholding has risen from 36.88% to 42.76%, indicating ongoing dilution or promoter stake reduction. Notably, FII holdings remain at 0% throughout all periods, and DII holdings are minimal (<3%), suggesting limited institutional interest. The rising number of shareholders (7,300 to 6,722) combined with low institutional participation may reflect retail-driven ownership and potential volatility in share price due to low float and concentration of promoter control.

⚖️ Peer Comparison — Pharmaceuticals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
SUNPHARMA	4.63 L Cr	38.3	18.7%	14.6%	0.05
DIVISLAB	2.43 L Cr	83.2	23.0%	17.4%	0.00
TORNTPHARM	1.89 L Cr	79.1	15.1%	25.7%	1.76
ZYDUSLIFE	1.16 L Cr	25.9	16.8%	16.6%	0.43
CIPLA	1.15 L Cr	34.0	13.2%	9.8%	0.01
LAURUSLABS	1.00 L Cr	91.8	20.8%	20.6%	0.45
LUPIN	98,305	17.4	27.9%	24.7%	0.26
DRREDDY	97,741	30.3	10.1%	8.4%	0.17
MANKIND	97,467	47.7	13.9%	12.7%	0.38
AUROPHARMA	96,836	26.3	12.8%	9.8%	0.20

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM ZYDUSLIFE CIPLA

⚠️ Risk Factors

1) The success of the nutraceutical expansion depends on shareholder approval at the 38th AGM and regulatory filings, which carry uncertainty given the promoter's historically dominant control (though holding has declined). 2) High leverage (D/E of 1.42) combined with entry into a capital-intensive, competitive segment increases financial vulnerability if new ventures fail to generate returns. 3) Absence of institutional ownership and low DII participation may lead to share price volatility and limited liquidity. 4) Management has not disclosed performance metrics or timelines for the new segment, creating execution risk.

📋 Recent Filings

🧠 Analyst's Read

Investors should monitor the outcome of the 38th AGM on 25 September 2026 and subsequent ROC filings to confirm the amendment's implementation, as this will be the first concrete step toward diversification. The company's financial trajectory remains flat, with growth reliant on the unproven nutraceutical venture, making execution risk a critical near-term catalyst.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on 530317

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts for your stocks — summarized by AI daily

Set up your AI Radar — pick stocks, get daily email summaries of new filings.

Set up AI Radar — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd